Novartis Stock Tanks Following Third Major Pipeline Setback
Novartis shares fell 10% on Thursday, marking a potential record daily loss following a third drug trial failure within seven days. The latest setback involves a Phase 3 study for a neuromuscular RNA drug intended to treat a rare muscle disease. This drug was part of a 12 billion dollar acquisition of Avidity. The series of pipeline disappointments has increased pressure on the pharmaceutical major as it faces multiple high-profile clinical failures in a short window.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Novartis shares dropped 10%.
- ✓ Novartis experienced three drug trial setbacks in one week.
- ✓ A neuromuscular RNA drug failed a key study for a rare muscle disease.
- ✓ The failed drug was part of a 12 billion dollar Avidity acquisition.
What changed
A neuromuscular RNA drug from Avidity failed a Phase 3 study, marking the third Novartis pipeline setback in a week.
Live updates
-
Novartis Stock Drops 10% After Third Pipeline Setback in One Week
Novartis shares fell 10% on Thursday, marking a potential record daily loss following a third drug trial failure within seven days. The latest setback involves a Phase 3 study for a neuromuscular RNA drug intended to treat a rare muscle disease. This drug was part of a 12 billion dollar acquisition of Avidity. The series of pipeline disappointments has increased pressure on the pharmaceutical major as it faces multiple high-profile clinical failures in a short window.
Why it matters
Pipeline setbacks directly impact a pharmaceutical company's future revenue projections and valuation. The failure of a Phase 3 trial is particularly significant because it is the final stage before regulatory approval. The high cost of the Avidity acquisition amplifies the financial impact of this specific drug failure.
What is confirmed
- Novartis shares dropped 10%.
- Novartis experienced three drug trial setbacks in one week.
- A neuromuscular RNA drug failed a key study for a rare muscle disease.
- The failed drug was part of a 12 billion dollar Avidity acquisition.
Still unconfirmed
- Novartis is heading for its worst day on record.
What to watch next
- Company statement regarding the future of the Avidity partnership
- Regulatory updates on other pipeline candidates
- Analyst revisions of Novartis stock price targets
confidence 95%Sources used for this update (7)
- CNBC — Pharma major Novartis plummets 10%, heading for worst day on record after three drug trial setbacks
- Reuters — Novartis shares sink on second pipeline setback this week
- Bloomberg.com — Novartis Sees Avidity Drug Fail in Third Setback in a Week
- Barron's — Novartis Stock Tanks Following Third Major Pipeline Setback
- STAT — Neuromuscular drug from Novartis fails in key study, adding to pressure on company
- BioSpace — Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
- BioPharma Dive — Novartis RNA drug falls short in rare muscle disease study
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community